Singapore, May 16 -- Aldevron, a global leader in the production of DNA, RNA and protein, together withIntegrated DNA Technologies(IDT), a global leader in genomics solutions, have announced the successful manufacture of the world's first personalised CRISPR gene editing drug product to treat an infant with urea cycle disorder (UCD).

With no current cure for UCDs, the Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania (Penn) engaged Aldevron and IDT, both part ofDanaher Corporation,to manufacture a novel mRNA-based personalised CRISPR therapy in six months-three times faster than the standard timeline for gene editing drug products.

The technically complex, N of 1 therapy required a new guide RNA (gRNA) sequen...